NDC 0378-4615 Doxylamine Succinate And Pyridoxine Hydrochloride

Doxylamine Succinate And Pyridoxine Hydrochloride

NDC Product Code 0378-4615

NDC CODE: 0378-4615

Proprietary Name: Doxylamine Succinate And Pyridoxine Hydrochloride What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Doxylamine Succinate And Pyridoxine Hydrochloride What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Product Characteristics

Color(s):
WHITE (C48325 - WHITE TO OFF-WHITE)
Shape: ROUND (C48348)
Size(s):
8 MM
Imprint(s):
M;DP
Score: 1

NDC Code Structure

  • 0378 - Mylan Pharmaceuticals Inc.
    • 0378-4615 - Doxylamine Succinate And Pyridoxine Hydrochloride

NDC Product Information

Doxylamine Succinate And Pyridoxine Hydrochloride with NDC 0378-4615 is a a human prescription drug product labeled by Mylan Pharmaceuticals Inc.. The generic name of Doxylamine Succinate And Pyridoxine Hydrochloride is doxylamine succinate and pyridoxine hydrochloride. The product's dosage form is tablet, delayed release and is administered via oral form.

Labeler Name: Mylan Pharmaceuticals Inc.

Dosage Form: Tablet, Delayed Release - A solid dosage form which releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed release dosage forms.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Doxylamine Succinate And Pyridoxine Hydrochloride Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • DOXYLAMINE SUCCINATE 10 mg/1
  • PYRIDOXINE HYDROCHLORIDE 10 mg/1

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • AMMONIA (UNII: 5138Q19F1X)
  • FERROSOFERRIC OXIDE (UNII: XM0M87F357)
  • HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
  • MAGNESIUM STEARATE (UNII: 70097M6I30)
  • MAGNESIUM TRISILICATE (UNII: C2E1CI501T)
  • METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A (UNII: NX76LV5T8J)
  • MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
  • POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)
  • POLYSORBATE 80 (UNII: 6OZP39ZG8H)
  • PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
  • SHELLAC (UNII: 46N107B71O)
  • TALC (UNII: 7SEV7J4R1U)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Oral - Administration to or by way of the mouth.
  • Oral - Administration to or by way of the mouth.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Antihistamine - [EPC] (Established Pharmacologic Class)
  • Histamine Receptor Antagonists - [MoA] (Mechanism of Action)
  • Vitamin B6 Analog - [EPC] (Established Pharmacologic Class)
  • Vitamin B 6 - [Chemical/Ingredient]
  • Analogs/Derivatives - [Chemical/Ingredient]

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Mylan Pharmaceuticals Inc.
Labeler Code: 0378
FDA Application Number: ANDA207825 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 07-06-2020 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2021 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Doxylamine Succinate And Pyridoxine Hydrochloride Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1 Indications And Usage

Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Limitations of Use: Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets have not been studied in women with hyperemesis gravidarum.

2.1 Dosage Information

Initially, take two doxylamine succinate and pyridoxine hydrochloride delayed-release tablets orally at bedtime (Day 1). If this dose adequately controls symptoms the next day, continue taking two tablets daily at bedtime. However, if symptoms persist into the afternoon of Day 2, take the usual dose of two tablets at bedtime that night then take three tablets starting on Day 3 (one tablet in the morning and two tablets at bedtime). If these three tablets adequately control symptoms on Day 4, continue taking three tablets daily. Otherwise take four tablets starting on Day 4 (one tablet in the morning, one tablet mid-afternoon and two tablets at bedtime). The maximum recommended dose is four tablets (one in the morning, one in the mid-afternoon and two at bedtime) daily. Take on an empty stomach with a glass of water [see Clinical Pharmacology (12.3)]. Swallow tablets whole. Do not crush, chew, or split doxylamine succinate and pyridoxine hydrochloride delayed-release tablets. Take as a daily prescription and not on an as needed basis. Reassess the woman for continued need for doxylamine succinate and pyridoxine hydrochloride delayed-release tablets as her pregnancy progresses.

3 Dosage Forms And Strengths

  • Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets are available containing 10 mg of doxylamine succinate, USP and 10 mg of pyridoxine hydrochloride, USP. •The 10 mg/10 mg tablets are white to off-white, film-coated, round, unscored tablets imprinted with M over DP in black ink on one side of the tablet and blank on the other side.

4 Contraindications

  • Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are contraindicated in women with any of the following conditions: •Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation •Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [see Drug Interactions (7.1)].

5.1 Activities Requiring Mental Alertness

Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets may cause somnolence due to the anticholinergic properties of doxylamine succinate, an antihistamine. Women should avoid engaging in activities requiring complete mental alertness, such as driving or operating heavy machinery, while using doxylamine succinate and pyridoxine hydrochloride delayed-release tablets until cleared to do so by their healthcare provider. Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets use is not recommended if a woman is concurrently using central nervous system (CNS) depressants including alcohol. The combination may result in severe drowsiness leading to falls or accidents [see Drug Interactions (7.1)].

5.2 Concomitant Medical Conditions

Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets have anticholinergic properties and, therefore, should be used with caution in women with: asthma, increased intraocular pressure, narrow angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction and urinary bladder-neck obstruction.

5.3 Interference With Urine Screen For Methadone, Opiates And Phencyclidine Phosphate (Pcp)

There have been reports of false positive urine screening tests for methadone, opiates, and PCP with doxylamine succinate/pyridoxine hydrochloride use [see Drug Interactions (7.3)].

6 Adverse Reactions

  • The following adverse reactions are discussed elsewhere in the labeling: •Somnolence [see Warnings and Precautions (5.1)] •Falls or other accidents resulting from the effect of the combined use of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets with CNS depressants including alcohol [see Warnings and Precautions (5.1)]

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety and efficacy of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets were compared to placebo in a double-blind, randomized, multi-center trial in 261 women with nausea and vomiting of pregnancy. The mean gestational age at enrollment was 9.3 weeks, range 7 to 14 weeks gestation [see Clinical Studies (14)]. Adverse reactions for doxylamine succinate and pyridoxine hydrochloride delayed-release tablets that occurred at an incidence ≥ 5 percent and exceeded the incidence for placebo are summarized in Table 1. Table 1: Number (Percent) of Subjects with ≥ 5 Percent Adverse Reactions in a 15-Day Placebo-Controlled Study of Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets (Only Those Adverse Reactions Occurring at an Incidence ≥ 5 Percent and at a Higher Incidence with Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets than Placebo are Shown)Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets(N = 133)Placebo(n = 128)Somnolence 19 (14.3%)15 (11.7%)

6.2 Postmarketing Experience

The following adverse events, listed alphabetically, have been identified during post-approval use of the combination of 10 mg doxylamine succinate and 10 mg pyridoxine hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiac Disorders: dyspnea, palpitation, tachycardia Ear and Labyrinth Disorders: vertigo Eye Disorders: vision blurred, visual disturbances Gastrointestinal Disorders: abdominal distension, abdominal pain, constipation, diarrhea General Disorders and Administration Site Conditions: chest discomfort, fatigue, irritability, malaise Immune System Disorders: hypersensitivity Nervous System Disorders: dizziness, headache, migraines, paresthesia, psychomotor hyperactivity Psychiatric Disorders: anxiety, disorientation, insomnia, nightmares Renal and Urinary Disorders: dysuria, urinary retention Skin and Subcutaneous Tissue Disorders: hyperhidrosis, pruritus, rash, rash maculo-papular

7.1 Drug Interactions

Use of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets is contraindicated in women who are taking monoamine oxidase inhibitors (MAOIs), which prolong and intensify the anticholinergic (drying) effects of antihistamines. Concurrent use of alcohol and other CNS depressants (such as hypnotic sedatives and tranquilizers) with doxylamine succinate and pyridoxine hydrochloride delayed-release tablets is not recommended.

7.2 Drug-Food Interactions

A food-effect study demonstrated that the delay in the onset of action of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets may be further delayed, and a reduction in absorption may occur when tablets are taken with food [see Dosage and Administration (2), Clinical Pharmacology (12.3)]. Therefore, doxylamine succinate and pyridoxine hydrochloride delayed-release tablets should be taken on an empty stomach with a glass of water [see Dosage and Administration (2)].

7.3 False Positive Urine Tests For Methadone, Opiates And Pcp

False positive drug screens for methadone, opiates, and PCP can occur with doxylamine succinate/pyridoxine hydrochloride use. Confirmatory tests, such as Gas Chromatography Mass Spectrometry (GC-MS), should be used to confirm the identity of the substance in the event of a positive immunoassay result.

Risk Summary

Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are intended for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Maternal risks are discussed throughout the labeling. No increased risk for congenital malformations has been reported in epidemiologic studies in pregnant women.In the U.S. general population, the estimated background risks for major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.

Human Data

The combination of doxylamine succinate and pyridoxine hydrochloride has been the subject of many epidemiological studies (cohort, case control and meta-analyses) designed to detect possible teratogenicity. A meta-analysis of 16 cohort and 11 case-control studies published between 1963 and 1991 reported no increased risk for malformations from first trimester exposures to doxylamine succinate and pyridoxine hydrochloride, with or without dicyclomine hydrochloride. A second meta-analysis of 12 cohort and 5 case-control studies published between 1963 and 1985 reported no statistically significant relationships between fetal abnormalities and the first trimester use of the combination doxylamine succinate and pyridoxine hydrochloride with or without dicyclomine hydrochloride.

8.2 Lactation

Women should not breastfeed while using doxylamine succinate and pyridoxine hydrochloride delayed-release tablets. The molecular weight of doxylamine succinate is low enough that passage into breast milk can be expected. Excitement, irritability and sedation have been reported in nursing infants presumably exposed to doxylamine succinate through breast milk. Infants with apnea or other respiratory syndromes may be particularly vulnerable to the sedative effects of doxylamine succinate and pyridoxine hydrochloride resulting in worsening of their apnea or respiratory conditions. Pyridoxine hydrochloride is excreted into breast milk. There have been no reports of adverse events in infants presumably exposed to pyridoxine hydrochloride through breast milk.

8.4 Pediatric Use

The safety and effectiveness of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets in children under 18 years of age have not been established. Fatalities have been reported from doxylamine overdose in children. The overdose cases have been characterized by coma, grand mal seizures and cardiorespiratory arrest. Children appear to be at a high risk for cardiorespiratory arrest. A toxic dose for children of more than 1.8 mg/kg has been reported. A 3 year old child died 18 hours after ingesting 1,000 mg doxylamine succinate. However, there is no correlation between the amount of doxylamine ingested, the doxylamine plasma level and clinical symptomatology.

10.1 Signs And Symptoms Of Overdose

Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are a delayed-release formulation, therefore, signs and symptoms of intoxication may not be apparent immediately. Signs and symptoms of overdose may include restlessness, dryness of mouth, dilated pupils, sleepiness, vertigo, mental confusion and tachycardia. At toxic doses, doxylamine exhibits anticholinergic effects, including seizures, rhabdomyolysis, acute renal failure and death.

10.2 Management Of Overdose

If treatment is needed, it consists of gastric lavage or activated charcoal, whole bowel irrigation and symptomatic treatment. For additional information about overdose treatment, call a poison control center (1-800-222-1222).

11 Description

Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are round, white to off-white, film-coated, delayed-release tablets containing 10 mg of doxylamine succinate and 10 mg of pyridoxine hydrochloride. Tablets are imprinted with M over DP in black ink on one side of the tablet and blank on the other side. Inactive ingredients are as follows: hypromellose, magnesium stearate, magnesium trisilicate, methacrylic acid copolymer dispersion, microcrystalline cellulose, polyethylene glycol, polysorbate 80, propylene glycol and talc. In addition, the black imprinting ink contains ammonium hydroxide, black iron oxide, propylene glycol and shellac glaze.Doxylamine Succinate: Doxylamine succinate is classified as an antihistamine. The chemical name for doxylamine succinate is 2-[α[2-(Dimethylamino)ethoxy]-α-methylbenzyl]pyridine succinate (1:1). The molecular formula is C17H22N2O • C4H6O4 and the molecular mass is 388.46. The structural formula is: Doxylamine succinate, USP is a white or almost white powder, having a characteristic odor, that is very soluble in water and alcohol, freely soluble in chloroform and very slightly soluble in ether and benzene. Pyridoxine Hydrochloride: Pyridoxine hydrochloride is a vitamin B6 analog. The chemical name for pyridoxine hydrochloride is 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride. The molecular formula is C8H12ClNO3 and the molecular mass is 205.6. The structural formula is: Pyridoxine hydrochloride, USP is white or practically white crystals or crystalline powder that is freely soluble in water, slightly soluble in alcohol and insoluble in ether.

12.1 Mechanism Of Action

The mechanism of action of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets is unknown.

12.3 Pharmacokinetics

The pharmacokinetics of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets have been characterized in healthy non-pregnant adult women. Pharmacokinetic results for doxylamine and pyridoxine, including its vitamin B6 metabolites, pyridoxal, pyridoxal 5’-phosphate, pyridoxamine and pyridoxamine 5’-phosphate, are summarized in Tables 2 to 5.

Absorption

A single-dose (two tablets) and multiple-dose (four tablets daily), open-label study was conducted to assess the safety and pharmacokinetic profile of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets administered in healthy non-pregnant adult women. Single-doses (two tablets at bedtime) were administered on Days 1 and 2. Multiple-doses (one tablet in the morning, one tablet in the afternoon and two tablets at bedtime) were administered on Days 3-18. Blood samples for pharmacokinetic analysis were collected pre-and post-dose on Days 2 and 18 as well as pre-dose prior to bedtime dose only (trough) on Days 9, 10, 11, 16, 17, and 18. Doxylamine and pyridoxine are absorbed in the gastrointestinal tract, mainly in the jejunum. The Cmax of doxylamine and pyridoxine are achieved within 7.5 and 5.5 hours, respectively (see Table 2). Table 2: Single-Dose and Multiple-Dose Pharmacokinetics of Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets in Healthy Non-Pregnant Adult WomenSingle DoseMultiple DoseAUC0-inf (ng•h/mL)Cmax (ng/mL)Tmax(h)AUC0-inf (ng•h/mL)Cmax (ng/mL)Tmax(h)Doxylamine1280.9 ± 369.383.3 ± 20.67.2 ± 1.93721.5 ± 1318.5168.6 ± 38.57.8 ± 1.6Pyridoxine43.4 ± 16.532.6 ± 15.05.7 ± 1.564.5 ±36.446.1 ± 28.35.6 ± 1.3Pyridoxal211.6 ± 46.174.3 ± 21.86.5 ± 1.41587.2 ± 550.0210.0 ± 54.46.8 ± 1.2Pyridoxal 5’-Phosphate1536.4 ± 721.530.0 ± 10.011.7 ± 5.36099.7 ± 1383.784.9 ± 16.96.3 ± 6.6Pyridoxamine4.1 ± 2.70.5 ± 0.75.9 ± 2.12.6 ± 0.80.5 ± 0.26.6 ± 1.4Pyridoxamine 5’-Phosphate5.2 ± 3.80.7 ± 0.514.8 ± 6.694.5 ± 58.02.3 ± 1.712.4 ± 11.2Multiple- dose administration of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets results in increased concentrations of doxylamine as well as increases in doxylamine Cmax and AUC0-last of absorption. The time to reach the maximum concentration is not affected by multiple doses. The mean accumulation index is more than 1.0 suggesting that doxylamine accumulates following multiple dosing (see Table 3). Although no accumulation was observed for pyridoxine, the mean accumulation index for each metabolite (pyridoxal, pyridoxal 5’-phosphate, and pyridoxamine 5’-phosphate) is more than 1.0 following multiple-dose administration of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets. The time to reach the maximum concentration is not affected by multiple doses (see Table 2).Table 3: Pharmacokinetics of Doxylamine and Pyridoxine Following Single Dose and Multiple Dose Administration of Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets to Healthy Non-Pregnant Adult WomenAUC0-last(ng•h/mL)AUC0-inf(ng•h/mL)Cmax(ng/mL)Tmax(h)T1/2el(h)Doxylamine Mean ± SDN = 18Single911.4 ± 205.61280.9 ± 369.383.3 ± 20.67.2 ± 1.910.1 ± 2.1Multiple3661.3 ± 1279.23721.5 ± 1318.5168.6 ± 38.57.8 ± 1.611.9 ± 3.3Pyridoxine Mean ± SD N = 18Single39.3 ± 16.543.4 ± 16.532.6 ± 15.05.7 ± 1.50.5 ± 0.2Multiple59.3 ± 33.964.5 ± 36.446.1 ± 28.35.6 ± 1.30.5 ± 0.1

Food Effect

The administration of food delays the absorption of both doxylamine and pyridoxine. This delay is associated with a lower peak concentration of doxylamine, but the extent of absorption is not affected (see Table 4). The effect of food on the peak concentration and the extent of absorption of the pyridoxine component is more complex because the pyridoxal, pyridoxamine, pyridoxal 5’-phosphate and pyridoxamine 5’-phosphate metabolites also contribute to the biological activity. Food significantly reduces the bioavailability of pyridoxine, lowering its Cmax and AUC by approximately 50% compared to fasting conditions. Similarly, food significantly reduces pyridoxal AUC and reduces its Cmax by 50% compared to fasting conditions. In contrast, food slightly increases pyridoxal 5’-phosphate Cmax and extent of absorption. As for pyridoxamine and pyridoxamine 5’-phosphate, the rate and extent of absorption seem to decrease under fed conditions. Table 4: Pharmacokinetics of Doxylamine and Pyridoxine Following Administration of Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets Under Fed and Fasted Conditions in Healthy Non-Pregnant Adult WomenAUC0-t (ng•h/mL)AUC0-inf (ng•h/mL)Cmax (ng/mL)Tmax(h)T1/2el(h)Doxylamine Mean ± SD N = 42Fasted1407.2 ± 336.91447.9 ± 332.294.9 ± 18.45.1 ± 3.412.6 ± 3.4Fed1488.0 ± 463.21579.0 ± 422.7N = 3775.7 ± 16.614.9 ± 7.412.5 ± 2.9Pyridoxine Mean ± SD N = 42Fasted33.8 ± 13.739.5 ± 12.9N = 3135.5 ± 21.42.5 ± 0.90.4 ± 0.2Fed18.3 ± 14.524.2 ± 14.0N = 1813.7 ± 10.89.3 ± 4.00.5 ± 0.2

Distribution

Pyridoxine is highly protein bound, primarily to albumin. Its main active metabolite, pyridoxal 5’-phosphate (PLP) accounts for at least 60% of circulating vitamin B6 concentrations.

Metabolism

Doxylamine is biotransformed in the liver by N-dealkylation to its principle metabolites N-desmethyl-doxylamine and N, N-didesmethyldoxylamine. Pyridoxine is a prodrug primarily metabolized in the liver.

Excretion

The principle metabolites of doxylamine, N-desmethyl-doxylamine and N, N-didesmethyldoxylamine, are excreted by the kidney. The terminal elimination half-life of doxylamine and pyridoxine are 12.5 hours and 0.5 hours, respectively (see Table 5). Table 5: Terminal Elimination Half-Life (T1/2el) for Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets Administered as a Single Dose of Two Tablets under Fasting Conditions in Healthy Non-Pregnant Adult WomenT1/2el(h)Doxylamine 12.6 ± 3.4Pyridoxine 0.4 ± 0.2Pyridoxal 2.1 ± 2.2Pyridoxal 5’-Phosphate 81.6 ± 42.2Pyridoxamine 3.1 ± 2.5Pyridoxamine 5’-Phosphate 66.5 ± 51.3

Race

No pharmacokinetic studies have been conducted related to race.

Hepatic Impairment

No pharmacokinetic studies have been conducted in hepatic impaired patients.i

Renal Impairment

No pharmacokinetic studies have been conducted in renal impaired patients.

Carcinogenicity

Two-year carcinogenicity studies in rats and mice have been conducted with doxylamine succinate. Doxylamine succinate is not likely to have human carcinogenic potential. The carcinogenic potential of pyridoxine hydrochloride has not been evaluated.

14 Clinical Studies

A double-blind, randomized, multi-center, placebo-controlled study was conducted to support the safety and efficacy of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets in the treatment of nausea and vomiting of pregnancy. Adult women 18 years of age or older and 7 to 14 weeks gestation (median 9 weeks of gestation) with nausea and vomiting of pregnancy were randomized to 14 days of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets or placebo. Two tablets of doxylamine succinate and pyridoxine hydrochloride were administered at bedtime on Day 1. If symptoms of nausea and vomiting persisted into the afternoon hours of Day 2, the woman was directed to take her usual dose of two tablets at bedtime that night and, beginning on Day 3, to take one tablet in the morning and two tablets at bedtime. Based upon assessment of remaining symptoms at her clinic visit on Day 4 (± 1 day), the woman may have been directed to take an additional tablet mid-afternoon. A maximum of four tablets (one in the morning, one in the mid-afternoon and two at bedtime) were taken daily. Over the treatment period, 19% of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets-treated patients remained on 2 tablets daily, 21% received 3 tablets daily, and 60% received 4 tablets daily. The primary efficacy endpoint was the change from baseline at Day 15 in the Pregnancy Unique-Quantification of Emesis (PUQE) score. The PUQE score incorporates the number of daily vomiting episodes, number of daily heaves, and length of daily nausea in hours, for an overall score of symptoms rated from 3 (no symptoms) to 15 (most severe). At baseline, the mean PUQE score was 9.0 in the doxylamine succinate and pyridoxine hydrochloride delayed-release tablets arm and 8.8 in the placebo arm. There was a 0.7 (95% confidence interval 0.2 to 1.2 with p-value 0.006) mean decrease (improvement in nausea and vomiting symptoms) from baseline in PUQE score at Day 15 with doxylamine succinate and pyridoxine hydrochloride delayed-release tablets compared to placebo (see Table 6). Table 6: Change from Baseline in the Primary Endpoint, Pregnancy Unique-Quantification of Emesis (PUQE) Score at Day 15. (Intent-to-Treat Population with Last-Observation Carried Forward)PUQE ScoreThe Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) score incorporated the number of daily vomiting episodes, number of daily heaves, and length of daily nausea in hours, for an overall score of symptoms rated from 3 (no symptoms) to 15 (most severe). Baseline was defined as the PUQE score completed at the enrollment visit.Doxylamine Succinate + Pyridoxine HydrochloridePlaceboTreatment Difference [95% Confidence Interval]BaselineChange from baseline at Day 159.0 ± 2.1-4.8 ± 2.78.8 ± 2.1-3.9 ± 2.6-0.7 [-1.2, -0.2]

16.1 How Supplied

Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets are available containing 10 mg of doxylamine succinate, USP and 10 mg of pyridoxine hydrochloride, USP.The 10 mg/10 mg tablets are white to off-white, film-coated, round, unscored tablets imprinted with M over DP in black ink on one side of the tablet and blank on the other side. They are available as follows:NDC 0378-4615-01bottles of 100 tablets

16.2 Storage And Handling

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Keep bottle tightly closed. Protect from moisture and light. Do not remove desiccant from bottle. Dispense in original container or equivalent air tight, light resistant container.

17 Patient Counseling Information

See FDA-approved patient labeling (Patient Information)Somnolence and Severe Drowsiness: Inform women to avoid engaging in activities requiring complete mental alertness, such as driving or operating heavy machinery, while using doxylamine succinate and pyridoxine hydrochloride delayed-release tablets until cleared to do so. Inform women of the importance of not taking doxylamine succinate and pyridoxine hydrochloride delayed-release tablets with alcohol or sedating medications, including other antihistamines (present in some cough and cold medications), opiates and sleep aids because somnolence could worsen leading to falls or other accidents. Interference with Urine Drug Screening: Inform women that use of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets may result in false positive urine drug screening for methadone, opiates and PCP.

Patient Information

  • Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-Release Tablets(dox il′ a meen sux′ i nate pir″ i dox′ een hye″ droe klor′ ide)What are doxylamine succinate and pyridoxine hydrochloride delayed-release tablets? •Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are a prescription medicine used to treat nausea and vomiting of pregnancy in women who have not improved with change in diet or other non-medicine treatments. •It is not known if doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are safe and effective in women with severe nausea and vomiting of pregnancy, a condition called hyperemesis gravidarum. Women with this condition may need to be hospitalized. •It is not known if doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are safe and effective in children under 18 years of age.Who should not take doxylamine succinate and pyridoxine hydrochloride delayed-release tablets?Do not take doxylamine succinate and pyridoxine hydrochloride delayed-release tablets if you: •are allergic to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any of the ingredients in doxylamine succinate and pyridoxine hydrochloride delayed-release tablets. See the end of this leaflet for a complete list of ingredients in doxylamine succinate and pyridoxine hydrochloride delayed-release tablets. •take monoamine oxidase inhibitors (MAOIs). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including Marplan®, Nardil®, Emsam®, Eldepryl®, Zelapar®, Parnate®.Before taking doxylamine succinate and pyridoxine hydrochloride delayed-release tablets, tell your healthcare provider about all of your medical conditions, including if you: •have asthma. •have eye problems called increased intraocular pressure or narrow angle glaucoma. •have a stomach problem called stenosing peptic ulcer or pyloroduodenal obstruction. •have a bladder problem called urinary bladder-neck obstruction. •are breastfeeding or plan to breastfeed.Doxylamine succinate and pyridoxine hydrochloride can pass into your breast milk and may harm your baby. You should not breastfeed while using doxylamine succinate and pyridoxine hydrochloride delayed-release tablets. Tell your healthcare provider about all the medicines you take, including prescription or over-the-counter medicines, vitamins, or herbal supplements.How should I take doxylamine succinate and pyridoxine hydrochloride delayed-release tablets? •Talk to your healthcare provider about how many doxylamine succinate and pyridoxine hydrochloride delayed-release tablets to take and when to take them. •Take doxylamine succinate and pyridoxine hydrochloride delayed-release tablets everyday as prescribed by your healthcare provider. Do not stop taking doxylamine succinate and pyridoxine hydrochloride delayed-release tablets without talking to your healthcare provider first. •See the following schedule for the usual way you should start taking doxylamine succinate and pyridoxine hydrochloride delayed-release tablets: •Day 1 - Take 2 tablets, by mouth at bedtime. •Day 2 - Take 2 tablets at bedtime. If your nausea and vomiting is better or controlled on Day 2, continue to take 2 tablets every night at bedtime. This will be your usual dose unless your healthcare provider tells you otherwise. •Day 3 - If you still had nausea and vomiting on Day 2, take 3 tablets on Day 3 (1 tablet in the morning and 2 tablets at bedtime). •Day 4 - If your nausea and vomiting was better or controlled on Day 3, continue to take 3 tablets each day (1 tablet in the morning and 2 tablets at bedtime). If you still had nausea and vomiting on Day 3, start taking 4 tablets each day (1 tablet in the morning, 1 tablet in the afternoon, and 2 tablets at bedtime). •Do not take more than 4 tablets (1 in the morning, 1 in the mid-afternoon, and 2 at bedtime) in 1 day. •Take doxylamine succinate and pyridoxine hydrochloride delayed-release tablets on an empty stomach with a glass of water. •Take doxylamine succinate and pyridoxine hydrochloride delayed-release tablets whole. Do not crush, chew, or break doxylamine succinate and pyridoxine hydrochloride delayed-release tablets before swallowing. If you cannot swallow doxylamine succinate and pyridoxine hydrochloride delayed-release tablets whole, tell your healthcare provider. •If you take too many doxylamine succinate and pyridoxine hydrochloride delayed-release tablets (overdose), you may have the following symptoms: restlessness, dry mouth, the pupils of your eyes become larger (dilated), sleepiness, dizziness, confusion, fast heart rate, seizures, muscle pain or weakness, and sudden and severe kidney problems. If you have these symptoms and they are severe, they may lead to death. Stop taking doxylamine succinate and pyridoxine hydrochloride delayed-release tablets, call your healthcare provider or go to the nearest hospital emergency room right away. For more information about overdose treatment, call your poison control center at 1-800-222-1222.What are the possible side effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets? Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets may cause serious side effects, including drowsiness. Drowsiness is a common side effect when taking doxylamine succinate and pyridoxine hydrochloride delayed-release tablets, but can also be severe: •Do not drive, operate heavy machinery, or other activities that need your full attention unless your healthcare provider says that you may do so. •Do not drink alcohol, or take other central nervous system depressants such as cough and cold medicines, certain pain medicines, and medicines that help you sleep while you take doxylamine succinate and pyridoxine hydrochloride delayed-release tablets. Severe drowsiness can happen or become worse causing falls or accidents.Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets may cause false positive urine drug screening test for methadone, opiates and PCP.These are not all the possible side effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.How should I store doxylamine succinate and pyridoxine hydrochloride delayed-release tablets? •Store doxylamine succinate and pyridoxine hydrochloride delayed-release tablets between 20° to 25°C (68° to 77°F). •Keep doxylamine succinate and pyridoxine hydrochloride delayed-release tablets dry, in a tightly closed container, and out of the light. •Safely throw away medicine that is out of date or no longer needed. Keep doxylamine succinate and pyridoxine hydrochloride delayed-release tablets and all medicines out of the reach of children.General information about the safe and effective use of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about doxylamine succinate and pyridoxine hydrochloride delayed-release tablets that is written for health professionals. Do not use doxylamine succinate and pyridoxine hydrochloride delayed-release tablets for a condition for which they were not prescribed. Do not give doxylamine succinate and pyridoxine hydrochloride delayed-release tablets to other people, even if they have the same symptoms that you have. They may harm them.What are the ingredients in doxylamine succinate and pyridoxine hydrochloride delayed-release tablets? Active ingredients: doxylamine succinate (an antihistamine) and pyridoxine hydrochloride (vitamin B6). Inactive ingredients: hypromellose, magnesium stearate, magnesium trisilicate, methacrylic acid copolymer dispersion, microcrystalline cellulose, polyethylene glycol, polysorbate 80, propylene glycol and talc. In addition, the black imprinting ink contains ammonium hydroxide, black iron oxide, propylene glycol and shellac glaze.For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX).Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.Manufactured by: Mylan Laboratories Limited, Hyderabad – 500 096, IndiaThis Patient Information has been approved by the U.S. Food and Drug AdministrationThe brands listed are trademarks of their respective owners.Manufactured for:Mylan Pharmaceuticals Inc.Morgantown, WV 26505 U.S.A.Manufactured by:Mylan Laboratories LimitedHyderabad – 500 096, India75059980Revised: 1/2019MX:DXPY:R1

* Please review the disclaimer below.